Corporate Benefits Become the New GLP-1 Battleground as Lilly Courts Employer Health Plans
I like the salary offer, but does your benefits package include unlimited Ozempic shots?
Job interviews are about to add another awkward benefits question after Eli Lilly unveiled a program aimed at helping employers cover obesity drugs… pushing the GLP-1 craze out of clinics and into corporate healthcare plans.
The drug giant calls it “Employer Connect.” Which sounds an awful lot like whoever came up with this idea has been spending way too much time on LinkedIn.
Here’s the basic problem Lilly is trying to solve.
Employers love the idea of healthier workers… fewer sick days… lower long-term healthcare costs… happier employees.
What they don’t love is paying $1,000+ a month so Dave from middle management (who’s never worked out a day in his life) can finally see his toes again.
Hence why Lilly built a platform that lets companies shop around for third-party administrators who manage obesity treatment benefits. Think of it like Expedia… but for weight-loss drugs.
Through the system, employers can connect with more than a dozen providers that help handle everything from eligibility checks to telehealth visits to nutrition programs.
And yes, some recognizable names are already hanging around the reverse buffet line. Partners include companies like GoodRx, Cost Plus Drug Company, Teladoc Health, and Sesame… along with a small army of startups promising to guide Americans through their pharmaceutical glow-up arc.
Each one offers the same Lilly drug at the same price. But they compete on the services around it… things like coaching, telehealth support, enrollment systems, and lifestyle programs.
The reason Lilly is doing this in the first place?
Employer coverage for GLP-1 drugs is still weirdly patchy.
Even though half the country seems fascinated with the “Hollywood skinny shot” phenomenon, Lilly says roughly half of people with commercial insurance still can’t access obesity treatments through their jobs. Definition of a “first world problem” amirite?
The price tag is the biggest reason. List prices for Lilly’s blockbuster injections (Zepbound and Mounjaro) run north of $1,000 per month. And we all know the average corporation ain’t shelling out that kind of cash just so Karen in accounting can avoid running on the treadmill.
So Lilly’s pitch is essentially this: “What if we could make the pricing predictable… and let companies design their own benefit plans?”
Under the new program, employers can grab a multi-dose version of Zepbound for roughly $449 a month… a number that’s still expensive, but no longer in the “I’m never going to financially recover from this” range like it was before.
The platform also sidesteps the traditional rebate maze drug companies usually hide behind. Which means fewer pricing shell games… and a much clearer answer to the question every CFO wants to know: “Can we afford this… or are we about to trigger a sudden outbreak of office romances now that half the company gets suspiciously hot?”
Meanwhile, Lilly’s chief rival and Ozempic druglord, Novo Nordisk, is reportedly chasing the same opportunity. Clearly the skinny-shot economy believes corporate America is the ultimate distribution channel. Also: if anyone has data on Golden Corral foot traffic since Ozempic launched… please share.
At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.